BCL2 and non-small cell lung carcinoma: Regarding the possible molecular mechanisms, we found that enhanced STAT3 activation resulted in increased Bcl-2 expression after gefitinib treatment (Fig 3A), which may be an important factor in primary or acquired resistance in NSCLC cells.